Janus Kinase Inhibitors

Janus Kinase Inhibitor

Arthritis, Rheumatoid

<section class="Section" data-sectioncode="34089-3"><a name="section-9"></a><h1>11 DESCRIPTION</h1>RINVOQ and RINVOQ LQ are formulated with upadacitinib, a JAK inhibitor. Upadacitinib has the following chemical name: (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate (2:1). The strength of upadacitinib is based on anhydrous upadacitinib. The solubility of upadacitinib in water is 38 to less than 0.2 mg/mL across a pH range of 2 to 9 at 37 oC. Upadacitinib has a molecular weight of 389.38 g/mol and a molecular formula of C17H19F3N6O • ½ H2O. The chemical structure of upadacitinib is: <img alt="upadacitinib-chem-structure" src="rinvoq-01.jpg"/>RINVOQ 15 mg extended-release tablets for oral administration are purple, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a15’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, ferrosoferric oxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 30 mg extended-release tablets for oral administration are red, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a30’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 45 mg extended-release tablets for oral administration are yellow to mottled yellow, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a45’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide yellow, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide.RINVOQ LQ oral solution for oral administration is a 1 mg/mL clear, colorless to light yellow solution. Each 1 mL RINVOQ LQ contains 1 mg of upadacitinib as free base (equivalent to 1.02 mg upadacitinib hemihydrate) and the following inactive ingredients: citric acid anhydrous, purified water, sodium benzoate, sodium citrate dihydrate, and sucralose. </section>

Rinvoq

upadacitinib

24 HR upadacitinib 15 MG Extended Release Oral Tablet

24 HR upadacitinib 15 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 30 MG Extended Release Oral Tablet

24 HR upadacitinib 30 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 45 MG Extended Release Oral Tablet

24 HR upadacitinib 45 MG Extended Release Oral Tablet [Rinvoq]

upadacitinib 1 MG/ML Oral Solution

upadacitinib 1 MG/ML Oral Solution [Rinvoq]

Upstate University Hospital  Downtown Campus

Actemra

Afinitor

Alecensa

Aranesp

Benlysta

Biktarvy

Bisulif

Braftovi

Brukinsa

Cabometyx

Calquence

Cosentyx

Enbrel

Epclusa

Epidolex

Erivedge

Erleada

Farydak

Fasenra

Gilotrif

Ibrance

Imbruvica

Inlyta

Inqovi

Jakafi

Kesimpta

Koselugo

Lenvima

Lonsurf

Lynparza

Mekinist

Nerlynx

Nexavar

Ninlaro

Nubeqa

Odomzo

Ofev

Olumiant

Onureg

Orgovyx

Piqray

Promacta

Retacrit

Retevmo

Rozlytrak

Rubraca

Somatuline Depot

Stelara

Stivarga

Sutent

Synagis

Tabrecta

Tafinlar

Tagrisso

Tarceva

Tasigna

Tavalisse

Tazverik

Temodar

Tibsovo

Trikfata

Tykerb

Venclexta

Verzenio

Votrient

Xospata

Xtandi

Yonsa

Zejula

Zelboraf

Rinvoq | Upstate University Hospital Downtown Campus

Does Upstate University Hospital Downtown Campus work closely with Rinvoq and AbbVie Inc.?

Does Upstate University Hospital Downtown Campus offer services for Rinvoq patients?

What conditions does Upstate University Hospital Downtown Campus support?

How does Upstate University Hospital Downtown Campus help with insurance?